A randomised, double-blind, placebo-controlled, 2-way crossover study to determine the efficacy of repeat inhaled doses of GW870086X on FEV1 in mild to moderate asthmatics

To determine the efficacy of repeat inhaled doses of GW870086X once daily for 28 days on FEV1 in mild to moderate asthmatics, compared with placebo